Microbiome Therapeutics Market, 2015 - 2030

  • ID: 3610690
  • Report
  • Region: Global
  • 218 Pages
  • Roots Analysis
1 of 5
Imbalance in the Natural Microbiota are a Known Cause for Many Chronic Diseases

FEATURED COMPANIES

  • 4D Pharma
  • c-LECta
  • GT Biologics
  • Mayo Clinic
  • OpenBiome
  • SporeGen
  • MORE
The ‘Microbiome Therapeutics Market, 2015-2030’ report provides a comprehensive study on the current landscape and the future outlook of the evolving pipeline of products in this area. Imbalance in the natural microbiota are a known cause for many chronic diseases such as antibiotic associated diarrhoea (AAD), Clostridium difficileinfections (CDI), irritable bowel syndrome (IBS), diabetes, Crohn’s disease and ulcerative colitis.

While the field has gathered the interest of several companies, there are no approved microbiome drugs available in the market yet; FMT is the only commercially available therapy. The development pipeline of microbiome therapeutics, though, has several promising candidates that are likely to result in commercial success stories in the foreseen future.

Among other elements, the report also elaborates on new microbiome based diagnostic solutions being developed and the upcoming opportunities in this market for different stakeholders. As pharmaceutical companies continue to initiate and expand their research programs in this area, one of the key objectives outlined for this report was to understand the future potential of the market. This was done by analysing:

- The microbiome therapeutic pipeline in terms of phase of development, type of products and indications.
- The epidemiology, patient population and available treatment plans for the potential therapeutic areas in this field.
- Partnerships that have taken place in the recent past covering research and development collaborations, product development and commercialisation agreements, license agreements, acquisitions and other relevant agreements.
- Various investments and grants received by companies focused in this area.
- The likely adoption of the microbiome therapeutics, the competition posed by the current treatment plans and the expected growth rate over the coming few years.

The study provides a detailed market forecast and opportunity analysis for the short-mid term (2015-2022) and long term (2022-2030). The research, analysis and insights presented in this report include potential sales of FMT therapies and drugs in late stages of development. Our opinions and insights, presented in this study, were influenced by several discussions we conducted with experts in this area.

These included senior representatives at Assembly Biosciences, Da Volterra, Metabiomics, MicroBiome Therapeutics and Rebiotix. All actual figures have been sourced and analysed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Example Highlights

- Overall, we have identified more than 100 microbiome products, in clinical and preclinical stages,which are being developed as therapeutic interventions for various disease areas. A healthy 27% of the pipeline accounts for molecules in clinical development; of these, majority are in phase II.
- In addition, we have captured several start-ups and small-sized firms that have taken initiatives in developing innovative microbiome based therapeutics. Notable examples include (in alphabetical order) AOBiome, Avid Biotics, C3 Jian, Da Volterra, OpenBiome, Procarta Biosystems, Rebiotix, Ritter Pharmaceuticals, Quorum Innovations, Seres Therapeutics, Symbiotic Health, Vedanta Biosciences, Xycrobe Therapeutics.
- Several firms are also developing microbiome related diagnostics and companion diagnostics. Examples include (in alphabetical order) Admera Health, Biocartis, Enterome Bioscience, Human Longevity, Metabiomics, Microbiome Diagnostics, Viomer, Whole Biome.
- Encouraging clinical results and unexplored opportunities have yielded an intense framework of investment activity with a sizeable number of venture capitalists actively supporting the research. In fact, during 2014 and 2015, there have been investments (equity + debt) of close to USD 0.7 billion.
- The microbiome therapeutics market is anticipated to grow aggressively with a healthy annual growth rate of 73% between 2015 and 2030. In the longer term, we expect the market to continue to rise steadily with high adoption rates of existing FMTs and emergence of novel microbiome related products.
- Additional analysis suggeststhat metabolic disorders and gastrointestinal (GI) disorders are the key therapeutic areas likely to garner a significant proportion of the overall market.

Chapter Outlines:

Chapter 2 provides an executive summary of the report. It offers a high level view on where the microbiome therapeutics market is headed in the mid to long term.

Chapter 3 provides a general introduction to the underlying concepts on the human microbiota. In addition to reviewing the function of microbiota, we have also discussed key aspects of the human microbiome project and the diseases caused by imbalance in the microbiota. Further, we have highlighted the need for microbiome therapeutics along with a brief description of the existing FMT therapies.

Chapter 4 includes information on over 100 molecules that are currently in different stages of development (both clinical and preclinical/discovery). In this section, we have presented a detailed analysis of the microbiome therapeutics development pipeline including information on the phase of development, indications and the type of products. In addition, the chapter contains details on different microbiome based diagnostics, medical foods and over-the-counter (OTC) supplements that are approved or under development.

Chapter 5 provides information on the various types of probiotic and prebiotic drugs that are being developed as microbiome therapeutics. It features a detailed discussion on their mode of action, range of formulations and the different disease areas likely to benefit from the use of these drugs.

Chapter 6 highlights the promising therapeutic areas for microbiome therapeutics. These indications are the prime focus of companies developing microbiome based drugs. The chapter also highlights the epidemiological facts and currently available treatment options for each indication.These therapeutic areas include gastrointestinal (GI) disorders, inflammatory disorders, metabolic disorders and women disorders.

Chapter 7 presents details on various investments and grants received by companies focused in the area of microbiome therapeutics. The analysis highlights the growing interest of the VC community and other strategic investors in this market.

Chapter 8 features an elaborate discussion on the collaborations and partnerships that have been forged amongst players in this market. We have also discussed the various partnership models in existence and the most common forms of deals/agreements that have evolved over time.

Chapter 9 highlights the monetary opportunity presented by these therapies.The analysis highlights the likely evolution of important parameters such as the target patient population and the likely market penetration rates. We have also presented an indicative distribution of the overall market across the well-known therapeutic areas.

Chapter 10 provides detailed company and drug profiles of the leading players in the market. Each profile includes information such as the company’s financial performance (wherever available), geographical presence, pipeline of microbiome therapeutics and recent collaborations.

Chapter 11 summarises the overall report. In this chapter, we provide a recap of the key takeaways and our independent opinion based on the research and analysis described in previous chapters.

Chapter 12 is a collection of interview transcripts of the discussions that were held with key stakeholders in this market. These include JP Benya (Vice President, Business Development of Assembly Biosciences),Pierre-Alain Bandinelli (Chief Business Officer of Da Volterra), Gregory J. Kuehn (Vice President, Business Development and Marketing of Metabiomics), Dr. Mark Heiman (Vice President of Research and Chief Scientific Officer of MicroBiome Therapeutics) and Lee Jones (President and CEO of Rebiotix).

Chapter 13 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter14 is an appendix, which provides the list of companies and organisations mentioned in the report.

READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 4D Pharma
  • c-LECta
  • GT Biologics
  • Mayo Clinic
  • OpenBiome
  • SporeGen
  • MORE
1. Preface
1.1. Scope Of The Report
1.2. Research Methodology
1.3. Chapter Outlines

2. Executive Summary

3. Introduction
3.1. Defining Microbiota and Microbiome
3.2. Discovery of the Human Microbiome
3.3. The Human Microbiome Project (HMP)
3.3.1. Project Approach
3.3.2. Project Initiatives
3.3.3. Project Achievements
3.4. Functions of the Human Microbiome
3.5. The Gut Flora
3.5.1. Role of Gut Microbiota
3.5.2. Imbalance in the Gut Flora
3.6. Development of Microbiota in Infants
3.6.1. Mode of Delivery
3.6.2. Type of Feeding
3.6.3. Use of Antibiotics by the Mother
3.7. Relationship between the Human Microbiome and Diseases
3.7.1. Cancer
3.7.2. Inflammatory Bowel Disease (IBD)
3.7.3. Obesity
3.7.4. Type-2 Diabetes
3.8. Need for Microbiome Therapies
3.9. Faecal Bacteriotherapy: A Powerful Tool to Restore Healthy Gut Microflora
3.9.1. FMT and FDA Regulation

4. Microbiome Therapeutics And Diagnostics: Market Landscape
4.1. Chapter Overview
4.1.1. Development Pipeline of Microbiome Therapeutics
4.1.1.1. Distribution by Phase of Development
4.1.1.2. Distribution by Type of Product
4.1.1.3. Distribution by Geography
4.1.1.4. Distribution by Therapeutic Area
4.1.1.5. Active Industry Players
4.1.2. Development Pipeline of Faecal Microbiota Transplant
4.1.3. Development Pipeline of Diagnostic Applications
4.1.4. Development Pipeline of Medical Food, Supplements and Consumer Products

5. Probiotic And Prebiotic Drugs
5.1. Chapter Overview
5.2. Probiotic Drugs
5.2.1. Introduction
5.2.2. Types of Probiotics
5.2.3. Therapeutic Areas Benefiting from Probiotics
5.2.3.1. Antibiotic-Associated Diarrhoea (AAD)
5.2.3.2. Infectious Childhood Diarrhoea
5.2.3.3. Cholesterol
5.2.3.4. Inflammatory Bowel Disease (IBD)
5.2.3.5. Blood Pressure
5.2.3.6. Lactose Intolerance
5.2.3.7. Weight Loss
5.2.3.8. Vitamin Production
5.2.3.9. Bacterial Vaginosis (BV)
5.2.4. Side Effects of Probiotics
5.3. Prebiotic Drugs
5.3.1. Introduction
5.3.2. Source of Prebiotics
5.3.3. Types of Prebiotics
5.3.3.1. Fructo-Oligosaccharides
5.3.3.2. Galacto-Oligosaccharides
5.3.3.3. Inulin
5.3.4. Therapeutic Areas Benefiting from Prebiotics
5.3.4.1. Antibiotic Associated Diarrhoea (AAD)
5.3.4.2. Constipation
5.3.4.3. Gastrointestinal (GI) Disorders
5.3.5. Dysbiosis
5.4. Development Pipeline of Probiotic/Prebiotic Drugs
5.4.1. Distribution by Phase of Development
5.4.2. Distribution by Therapeutic Area
5.4.3. Distribution by Geography
5.4.4. Distribution by Company

6. Key Therapeutic Areas
6.1. Chapter Overview
6.2. Gastrointestinal (GI) Disorders
6.2.1. Clostridium difficile Infections (CDI)
6.2.1.1. Disease Description
6.2.1.2. Epidemiology
6.2.1.3. Current Treatment Plans
6.2.1.4. Microbiome Therapies for CDIs and Other Hospital Acquired Diseases
6.2.2. Irritable Bowel Syndrome (IBS)
6.2.2.1. Disease Description
6.2.2.2. Epidemiology
6.2.2.3. Current Treatment Plans
6.2.2.4. Microbiome Therapies for IBS
6.3. Inflammatory Disorders
6.3.1. Ulcerative Colitis
6.3.1.1. Disease Description
6.3.1.2. Epidemiology
6.3.1.3. Current Treatment Plans
6.3.1.4. Microbiome Therapies for Ulcerative Colitis
6.3.2. Crohn's Disease
6.3.2.1. Disease Description
6.3.2.2. Epidemiology
6.3.2.3. Current Treatment Plans
6.3.2.4. Microbiome Therapies for Crohn's Disease
6.4. Metabolic Disorders
6.4.1. Diabetes
6.4.1.1. Disease Description
6.4.1.2. Epidemiology
6.4.1.3. Current Treatment Plans
6.4.1.4. Microbiome Therapies for Diabetes
6.4.2. Obesity
6.4.2.1. Disease Description
6.4.2.2. Epidemiology
6.4.2.3. Current Treatment Plans
6.4.2.4. Microbiome Therapies for Obesity
6.5. Women Disorders
6.5.1. Bacterial Vaginosis (BV)
6.5.1.1. Disease Description
6.5.1.2. Epidemiology
6.5.1.3. Current Treatment Plans
6.5.1.4. Microbiome Therapies for BV

7. Venture Capital Interest
7.1. Chapter Overview
7.2. Instances of Funding for Development of Microbiome Therapeutics and Diagnostics
7.3. Rising Venture Capital Interest
7.4. Funding Instances: Distribution by Type of Funding
7.5. Leading Players: Distribution by Number of Funding Instances
7.6. Most Active VC Firms/Institutions
7.7. Most of the Funding is Targeted Towards Therapeutic Applications

8. Recent Collaborations
8.1. Chapter Overview
8.2. Partnership Models/Agreements
8.3. Microbiome Therapies: Recent Collaborations
8.4. Distribution by Month/Year
8.5. Distribution by Type of Application
8.5.1. Distribution by Type of Therapeutic Product
8.6. Distribution by Type of Partnership
8.7. Most Active Companies with Multiple Collaborations

9. Market Sizing And Opportunity Analysis
9.1. Chapter Overview
9.2. Forecast Methodology
9.3. Microbiome Therapeutics Market: Key Assumptions
9.4. Microbiome Therapeutics Market: Opportunity Analysis
9.4.1. Overall Microbiome Therapeutics Market, 2015-2030
9.4.2. Microbiome Therapeutics Market, 2015-2030: Distribution by Therapeutic Area
9.4.3. Microbiome Therapeutics Market, 2015-2030: Distribution by Application

10. Company Profiles
10.1. Chapter Overview
10.2. C3 Jian
10.2.1. Company Overview
10.2.2. Product Portfolio
10.2.2.1. Therapeutics
10.2.2.2. Diagnostics
10.3. Enterome Bioscience
10.3.1. Company Overview
10.3.2. Product Portfolio
10.3.2.1. Therapeutics
10.3.2.2. Diagnostics
10.3.3. Collaborations
10.4. Immuron
10.4.1. Company Overview
10.4.2. Financial Performance
10.4.3. Product Portfolio
10.4.4. Collaborations
10.5. MicroBiome Therapeutics
10.5.1. Company Overview
10.5.2. Product Portfolio
10.6. OpenBiome
10.6.1. Company Overview
10.6.2. Financial Performance
10.6.3. Product Portfolio
10.7. Osel
10.7.1. Company Overview
10.7.2. Product Portfolio
10.7.3. Collaborations
10.8. Rebiotix
10.8.1. Company Overview
10.8.2. Product Portfolio
10.8.3. Collaborations
10.9. Ritter Pharmaceuticals
10.9.1. Company Overview
10.9.2. Financial Performance
10.9.3. Product Portfolio
10.9.4. Collaborations
10.10. Second Genome
10.10.1. Company Overview
10.10.2. Second Genome Solutions
10.10.3. Product Portfolio
10.10.4. Collaborations
10.11. Seres Therapeutics
10.11.1. Company Overview
10.11.2. Financial Performance
10.11.3. Product Portfolio
10.11.4. Collaborations
10.12. Synthetic Biologics
10.12.1. Company Overview
10.12.2. Financial Performance
10.12.3. Product Portfolio
10.12.4. Collaborations/Recent Developments

11. Conclusion
11.1. Imbalance in the Human Microbiota Leading to Rising Chronic Disorders
11.2. Increasing Antibiotic Use is The Primary Cause of Microflora Disturbance
11.3. Microbiome Therapy Offers a Potential Solution to Preserve the Human Microflora
11.4. Several Initiatives are Still in Early Stages of Development
11.5. An Active Support from Regulatory Authorities Likely to Drive High Accessibility
11.6. With a Strong Preclinical Backup, We Expect Steady Growth in the Coming Years

12. Interview Transcripts
12.1. Chapter Overview
12.2. JP Benya, Vice President, Business Development, Assembly Biosciences
12.3. Pierre-Alain Bandinelli, Chief Business Officer, Da Volterra
12.4. Gregory J. Kuehn, Vice President, Business Development and Marketing, Metabiomics
12.5. Dr. Mark Heiman, Vice President of Research and Chief Scientific Officer, MicroBiome Therapeutics
12.6. Lee Jones, President and CEO, Rebiotix

13. Appendix 1: Tabulated Data

14. Appendix 2: List Of Companies And Organisations

List of Figures

Figure 3.1 Achievements of the Human Microbiome Project

Figure 3.2 Factors Affecting the Gut Flora

Figure 3.3 Factors Affecting the Infant Gut Microbiota

Figure 4.1 Microbiome Therapeutics: Distribution by Phase of Development

Figure 4.2 Microbiome Therapeutics: Distribution by Type of Product

Figure 4.3 Microbiome Therapeutics: Distribution by Geography

Figure 4.4 Microbiome Therapeutics: Distribution by Therapeutic Area

Figure 4.5 Microbiome Therapeutics: Distribution by Therapeutic Area and Phase of Development

Figure 4.6 Microbiome Therapeutics: Active Industry Players

Figure 5.1 Probiotic Drugs: Modes of Action

Figure 5.2 Probiotic and Prebiotic Drugs: Distribution by Number of Products

Figure 5.3 Probiotic and Prebiotic Drugs: Distribution by Phase of Development

Figure 5.4 Probiotic and Prebiotic Drugs: Distribution by Therapeutic Area

Figure 5.5 Probiotic and Prebiotic Drugs: Distribution by Geography

Figure 5.6 Probiotic and Prebiotic Drugs: Active Industry Players

Figure 6.1 Clostridium difficile Infections (CDI): Pipeline by Product Type and Development Stage

Figure 6.2 Irritable Bowel Syndrome (IBS): Pipeline by Product Type and Development Stage

Figure 6.3 Diabetes: Pipeline by Product Type and Development Stage

Figure 7.1 Number of Funding Instances by Year, 2005 Onwards

Figure 7.2 Amount Invested by Year, 2005 Onwards

Figure 7.3 Funding Instances: Distribution by Type, 2005-2015

Figure 7.4 Funding Instances: Distribution by Total Amount Invested, 2005-2015 (USD Million)

Figure 7.5 Funding Instances: Distribution by Range of Amount Invested by Type of Funding (USD Million)

Figure 7.6 Most Active Players: Distribution by Number of Funding Instances, 2005-2015

Figure 7.7 Most Active VC Firms/Investors: Distribution by Number of Instances, 2005, 2015

Figure 7.8 Funding Instances: Distribution by Type of Application

Figure 7.9 Funding Instances: Distribution by Type of Product

Figure 8.1 Recent Collaborations: Distribution by Year

Figure 8.2 Recent Collaborations: Distribution by Type of Application

Figure 8.3 Recent Collaborations: Distribution by Type of Therapeutic Product

Figure 8.4 Recent Collaborations: Distribution by Type of Model

Figure 8.5 Recent Collaborations: Distribution by Company

Figure 9.1 Microbiome Therapeutics Market Forecast (USD Million), Short Term, Base Case, 2015 - 2022

Figure 9.2 Microbiome Therapeutics Market Forecast (USD Million), Mid-Long Term, Base Case, 2022 – 2030

Figure 9.3 Microbiome Therapeutics Market: Distribution by Therapeutic Area, 2025, 2030

Figure 9.4 Microbiome Therapeutics Market: Distribution by Function, 2030

Figure 10.1 Advantages of Different Formulations of C16G2

Figure 10.2 OpenBiome: Revenues 2014, Distribution by Different Segments (USD Million)

Figure 10.3 Second Genome Solutions Program

Figure 11.1 Microbiome Therapeutics Market (USD Million), 2015, 2022, 2030

List of Tables

Table 3.1 Microbiota in the GI Tract

Table 4.1 Microbiome Therapeutics: Development Pipeline

Table 4.2 FMT Therapies: Development Pipeline

Table 4.3 Microbiome Diagnostics: Development Pipeline

Table 4.4 Microbiome Based Medical Food Supplements and Consumer Products for Humans: Development Pipeline

Table 5.1 Foods Containing Prebiotics

Table 5.2 Probiotic and Prebiotic Drugs: Development Pipeline

Table 6.1 Clostridium difficile Infections (CDI): Diagnostic Tests

Table 6.2 Clostridium difficile Infections (CDI) and Other Hospital Acquired Infections: Microbiome Therapeutics Pipeline

Table 6.3 Irritable Bowel Syndrome (IBS): Current Medication

Table 6.4 Irritable Bowel Syndrome (IBS): Microbiome Therapeutics Pipeline

Table 6.5 Ulcerative Colitis: Microbiome Therapeutics Pipeline

Table 6.6 Crohn’s Disease: Current Medication

Table 6.7 Crohn’s Disease: Microbiome Therapeutics Pipeline

Table 6.8 Diabetes: Current Medications

Table 6.9 Diabetes: Microbiome Therapeutics Pipeline

Table 6.10 Obesity: Microbiome Therapeutics Pipeline

Table 6.11 Bacterial Vaginosis (BV): Current Medication

Table 6.12 Bacterial Vaginosis (BV): Microbiome Therapeutics Pipeline

Table 7.1 List of Funding Instances and Investors, 2005-2015

Table 7.2 Types of Funding Instances, 2005- 2015

Table 7.3 Amount Invested by Product Type, 2005- 2015 (USD Million)

Table 8.1 Microbiome Therapies: Recent Collaborations (2005-2015)

Table 9.1 Potential Therapeutic Areas: Estimated Market Growth Rate

Table 9.2 Potential Therapeutic Areas: Estimated Penetration (By 2030)

Table 10.1 C3 Jian: Product Portfolio, Microbiome Therapeutics

Table 10.2 Different Formulations of C16G2

Table 10.3 C3 Jian: Product Portfolio, Microbiome Diagnostics

Table 10.4 Enterome Bioscience: Product Portfolio, Microbiome Therapeutics

Table 10.5 Enterome Bioscience: Product Portfolio, Microbiome Diagnostics

Table 10.6 Immuron: Product Portfolio, Microbiome Therapeutics

Table 10.7 MicroBiome Therapeutics: Product Portfolio, Microbiome Therapeutics

Table 10.8 OpenBiome: Product Portfolio, FMT

Table 10.9 FMP 30: Specifications

Table 10.10 FMP 250: Specifications

Table 10.11 Osel: Product Portfolio, Microbiome Therapeutics

Table 10.12 Rebiotix: Product Portfolio, Microbiome Therapeutics

Table 10.13 Ritter Pharmaceuticals: Product Portfolio, Microbiome Therapeutics

Table 10.14 Second Genome: Product Portfolio, Microbiome Therapeutics

Table 10.15 Seres Therapeutics: Product Portfolio, Microbiome Therapeutics

Table 10.16 Synthetic Biologics: Product Portfolio, Microbiome Therapeutics

Table 13.1 Microbiome Therapies: Distribution by Phase of Development

Table 13.2 Microbiome Therapies: Distribution by Type of Product

Table 13.3 Microbiome Therapies: Distribution by Geography

Table 13.4 Microbiome Therapies: Distribution by Therapeutic Area

Table 13.5 Microbiome Therapeutics: Distribution by Therapeutic Area and Phase of Development

Table 13.6 Microbiome Therapeutics: Active Industry Players

Table 13.7 Probiotic and Prebiotic Drugs: Distribution by Numbers of Products

Table 13.8 Probiotic and Prebiotic Drugs: Distribution by Phase of Development

Table 13.9 Probiotic and Prebiotic Drugs: Active Industry Players

Table 13.10 Probiotic and Prebiotic Drugs: Distribution by Geography

Table 13.11 Probiotic and Prebiotic Drugs: Active Industry Players

Table 13.12 Clostridium difficile Infections (CDI): Pipeline by Product Type and Development Stage

Table 13.13 Irritable Bowel Syndrome (IBS): Pipeline by Product Type and Development Stage

Table 13.14 Diabetes: Pipeline by Product Type and Development Stage

Table 13.15 Number of Funding Instances by Year, 2005 Onwards

Table 13.16 Amount Invested by Year, 2005 Onwards

Table 13.17 Funding Instances: Distribution by Type, 2005-2015

Table 13.18 Funding Instances: Distribution by Total Amount Invested, 2005-2015 (USD Million)

Table 13.19 Most Active Players: Distribution by Number of Funding Instances, 2005-2015

Table 13.20 Most Active VC Firms/Investors: Distribution by Number of Instances, 2005-2015

Table 13.21 Funding Instances: Distribution by Type of Application

Table 13.22 Funding Instances: Distribution by Type of Product

Table 13.23 Recent Collaborations: Distribution by Year

Table 13.24 Recent Collaborations: Distribution by Type of Application

Table 13.25 Recent Collaborations: Distribution by Type of Therapeutic Product

Table 13.26 Recent Collaborations: Distribution by Type of Model

Table 13.27 Recent Collaborations: Distribution by Company

Table 13.28 Microbiome Therapeutics Market Forecast (USD Million), Short Term, Base Case, 2015-2022

Table 13.29 Microbiome Therapeutics Market Forecast (USD Million), Short Term, Conservative Case, 2015-2022

Table 13.30 Microbiome Therapeutics Market Forecast (USD Million), Short Term, Optimistic Case, 2015-2022

Table 13.31 Microbiome Therapeutics Market Forecast (USD Million), Mid-Long Term, Base Case, 2022-2030

Table 13.32 Microbiome Therapeutics Market Forecast (USD Million), Mid-Long Term, Conservative Case, 2022-2030

Table 13.33 Microbiome Therapeutics Market Forecast (USD Million), Mid-Long Term, Optimistic Case, 2022-2030

Table 13.34 Microbiome Therapeutics Market: Distribution by Therapeutic Area, 2025, 2030

Table 13.35 Microbiome Therapeutics Market: Distribution by Function, 2030

Table 13.36 OpenBiome: Revenues 2014, Distribution by Different Segments (USD Million)

Table 13.37 Microbiome Therapeutics Market (USD million), 2015, 2022, 2030
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • 4D Pharma
  • c-LECta
  • GT Biologics
  • Mayo Clinic
  • OpenBiome
  • SporeGen
  • MORE
The term “microbiota” refers to specific clusters of commensal, symbiotic and pathogenic microorganisms that reside in various regions on and within the human body. The human microbiome is involved in various functions that are essential to lead a healthy life. Majority of the microorganisms benefit humans by supplementing them with traits that they would otherwise not possess. These include metabolism of complex carbohydrates, renewal of gut epithelial cells and prevention of growth of pathogens.

However, several microorganisms are associated with pathogenic organisms or have the capability of translating into a disease-causing microbe.In fact, an imbalance in the human flora or dysbiosis is also seen to be associated with several long-term diseases. During dysbiosis, it is observed that with the reducing number of beneficial microbes, there is a concurrent increase in the number of harmful microbes. The increase in the number of pathogenic microbes further leads to the development of several harmful diseases such as inflammatory bowel disease (IBD), cancer, bacterial vaginosis (BV), obesity and chronic fatigue syndrome.

In addition to the existing treatment plans for such health conditions, approaches that modify natural formulations by adding or removing individual microbes or entire microbial communities have been shown to have a significant impact on the health of an individual. Usingmicrobiome as a therapy has unique advantages over traditional small molecules or biologics.

It can be used to identify individual therapeutic microorganisms and help in designing the therapies customised to the patient’s microbiome. Unlike the adverse effects posed by the prolonged use of drugs such as the antibiotics, microbiome therapeutics have a lower risk of toxicity associated with them. In addition, microbiome based therapies provide a rich source of new biomarkers helping in the classification of the patients into relatively homogeneous subpopulations.

Currently, there are many popular probiotics, prebiotics, medical food and supplements commercially available in the market as OTC products. These products are known to prevent a number of diseases by restoring the human microbiome to its natural state. However, these products cannot be used as a replacement for medication or as a treatment for the eradication of the disease. The overall microbiome therapeutics market is still in its infancy with no approved drugs; Faecal microbial transplant (FMT) is the only microbiome related therapy that has entered the market. With several firms and investors displaying a growing interest in this field, the overall market holds a strong potential in the coming years.

Research Methodology:

Most of the data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include

- Annual reports
- Investor presentations
- SEC filings
- Industry databases
- News releases from company websites
- Government policy documents
- Industry analysts’ views

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Note: Product cover images may vary from those shown
5 of 5
- 4D Pharma
- AOBiome
- APC Microbiome Institute
- AbbVie
- ActoGeniX
- Admera Health
- Advanced Technology Ventures
- Advancing Bio
- AgBiome
- Assembly Biosciences
- Avid Biotics
- Azitra
- BTER Foundation
- Baylor College of Medicine
- Beth Israel Deaconess Medical Center
- Bill and Melinda Gates Foundation
- BioAster Technology Research Institute
- BioBalance Corporation
- BioConsortia
- BioGaia
- Biocartis
- Biomecite Diagnostics
- Boston Children's Hospital
- Boston Medical Center
- Brigham and Women's Hospital
- Bright Medicine Clinic
- Broad Institute
- C3 Jian
- Cedars-Sinai Medical Center (CSMC)
- Center for Biologics Evaluation and Research (CBER)
- Center for Disease Control and Prevention
- Cipac Therapeutics
- Cleveland Clinic
- Commonwealth Scientific and Industrial Research Organisation(CSIRO)
- Companion PBx
- Concorde Medical Group
- Crohn's and Colitis Foundation of America (CCFA)
- Da Volterra
- Dairy Innovation Australia Limited (DIAL)
- Danisco
- Debiopharm
- Defence Advanced Research Projects Agency (DARPA)
- Dermala
- Duke University
- Enso Ventures
- Enterologics
- Enterome BioScience
- Epibiome
- Epiva Therapeutics
- Evelo Therapeutics
- Evolve Biosystems
- Evotec
- ExeGi Pharma
- FUJIFILM Diosynth Biotechnologies
- Flagship Ventures
- Food and Agricultural Organisation (FAO)
- GMU Microbiome Analysis Center (MBAC)
- GT Biologics
- Gallinee
- Genetic Analysis
- Genewiz
- Gustave Roussy
- Hadassah Medical Center
- Hospital Oberndorf
- Human Longevity
- Hy Laboratories
- INRA National Institute for Agronomic Research
- Igen Biotech Group
- Illumina Accelerator
- Immune Biologics
- Immuron
- Indiana University
- Inocucor Technologies
- Inserm
- Institut De Recherche Pour Le Developent (IRD)
- Institut Merieux
- Institute for Biomedical Research Dr JosepTrueta of Girona
- Institute of Cardio metabolism and Nutrition (ICAN)
- International Agency for Research on Cancer (IARC)
- Intrexon
- J. Craig Venter Institute
- Janssen
- Johnson & Johnson Innovation Center
- KOLUPOHAKU TECHNOLOGIES (KPT)
- Kindstar Global
- Lille Teaching Hospital (CHRU)
- Lundbeckfond Ventures
- MBcure
- MaaT Pharma
- Macau University of Science and Technology
- Manzo Pharmaceuticals
- Matatu
- Mayo Clinic
- Medical University Innsbruck
- Merck
- Metabiomics
- Metabogen
- Metabolon
- Metanome
- Metrodora Therapeutics
- MiOmics
- MicroBiome Therapeutics
- Microbiome
- Microbiome Diagnostics
- Microbiota Company
- Miyarisan Pharmaceutical
- Monarch Labs
- Monash University
- MonterFiore Medical Research Center of Connecticut
- Morgenthaler
- MyBiotics
- NIZO Food Research
- National Center for Health Statistics (NCHS)
- National Health Service (NHS)
- National Institute of Allergic and Infectious Diseases (NIAID)
- National Institute of Health (NIH)
- Novartis
- OmniBiome Therapeutics
- One Way Liver
- OpenBiome
- OptiBiotix Health
- Oragenics
- Osel
- OxThera
- Pasteur Institute
- Pfizer
- Pivot Bio
- Prev AbR
- Procarta Biosystems
- PureFlora
- Quorum Innovations
- Rebiotix
- Ritter Pharmaceuticals
- Rush University Medical Center
- Second Genome
- Sen Nuo Wei Biotechnology
- Seres Therapeutics
- Servier
- Seventure
- Shire
- Shoreline Biome
- Sigma-Tau Pharmaceuticals
- SporeGen
- Swecure
- Symberix
- Symbiota
- Symbiotix Biotherapies
- Synlogic
- Synthetic Biologics
- TargEDys
- Therapeutic Solutions International
- TriPhase Pharmaceuticals
- UAS Labs
- Universal Stabilisation Technologies
- Universite Pierre Et Marie Curie (UPMC)
- University of California, San Diego (UCSD)
- University of Chicago
- University of Guelph
- University of Maryland (UM) Ventures
- University of Rome Tor Vergata
- University of Virginia
- VSL Pharmaceuticals
- Vaiomer
- Vedanta Biosciences
- Virginia Commonwealth University
- ViroPharma Incorporated
- Vithera Pharmaceuticals
- Washington University School of Medicine
- Wavepoint Ventures
- Weizmann Institute
- Whole Biome
- World Gastroenterology Organisation (WGO)
- World Health Organisation (WHO)
- Wyss Institute
- Xycrobe Therapeutics
- Yakult Honsha
- c-LECta

Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll